🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Genetic Mutations

Found 2516 matching trials

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations

PHASE1

A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, and Effic...

Status

Not Yet Recruiting

Location

Xiangya Hospital, Central South University

Start Date

2026-05-25

Trial ID

NCT07414290

Treatments Being Tested

VGN-R08b 4.2×10^13 vg VGN-R08b 8.4×10^13 vg VGN-R08b 1.68×10^14 vg

Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

PHASE1

This clinical trial aims to evaluate the safety, immunogenicity, and prelim...

Status

Completed

Location

Vejthani Hospital

Start Date

2022-11-24

Trial ID

NCT06614140

Treatments Being Tested

Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors

Gene Study for Infantile Onset Diabetes

N/A

Diabetes mellitus is a group of metabolic diseases characterized by chronic...

Status

Unknown

Location

Multiple Locations

Start Date

2018-01

Trial ID

NCT03169413

Treatments Being Tested

Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

PHASE2

This study is open to adults with a type of kidney disease called focal seg...

Status

Completed

Location

Nephrology Consultants, LLC

Start Date

2022-05-03

Trial ID

NCT05213624

Treatments Being Tested

BI 764198 Placebo

Tailored Vs. Empirical Helicobacter Pylori Infection Treatment

PHASE4

Helicobacter pylori (Hp) is a gram-negative bacterium that colonizes human ...

Status

Not Yet Recruiting

Location

Unilabs Portugal

Start Date

2025-09

Trial ID

NCT06200779

Treatments Being Tested

Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days Bismuth quadruple therapy (Pylera®) for 10 days

Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)

This randomized controlled trial aims to evaluate the impact of pre-test vi...

Status

Completed

Location

Dana-Farber Cancer Institute

Start Date

2017-11-21

Trial ID

NCT03328091

Treatments Being Tested

Traditional pre-test genetic counseling Pre-test video education

Mutations, Hormone Therapy (HRT) and Venous Thromboembolism

N/A

To assess the interaction between hormone replacement therapy and the proth...

Status

Completed

Location

Multiple Locations

Start Date

1998-09

Trial ID

NCT00005515

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

N/A

Observe the efficacy and safety of sunvozertinib in the real world in the t...

Status

Not Yet Recruiting

Location

Qiming Wang

Start Date

2025-02-01

Trial ID

NCT06786208

Treatments Being Tested

Sunvozertinib

Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

PHASE2

This is a multi-center, prospective, single-arm, non-randomized, interventi...

Status

Active Not Recruiting

Location

Universitätsklinikum Jena

Start Date

2026-06-22

Trial ID

NCT07789574

Treatments Being Tested

asciminib 200 mg BID

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

PHASE2

The study will assess the safety and efficacy of single-agent MEK162 in adu...

Status

Completed

Location

Highlands Oncology Group

Start Date

2011-03-24

Trial ID

NCT01320085

Treatments Being Tested

MEK162

Previous Next